ArticleInfection and drug resistance2026
Comparative in vitro Activity and Clinical Outcomes of Eravacycline, Tigecycline, and Omadacycline Against Carbapenem-Resistant
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review.Journal of clinical medicine · 2026Review
- Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections.Antibiotics (Basel, Switzerland) · 2026Review
- Eravacycline-Cefiderocol Combination Therapy for Carbapenem-ResistantInfection and drug resistance · 2026Article
- Clinical Characteristics, Antimicrobial Resistance Profiles and Carbapenemases Genotypes ofInfection and drug resistance · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Carbapenem-resistant Patients and Methods: A total of 106 CRKP and 117 CRAB non-duplicate clinical isolates were collected from Xuanwu Hospital (Beijing) between December 2024 and June 2025. Minimum inhibitory concentrations (MICs) were determined using broth microdilution (CLSI M07 guidelines). Time-kill assays (0-48 h) were used to evaluate bactericidal activity, and clinical outcomes were analyzed in patients treated with TGC or ERV. Results: ERV demonstrated superior in vitro activity: its MIC Conclusion: Current evidence indicates that ERV exhibits strong in vitro bactericidal activity and demonstrates more favorable clinical efficacy comparable to that of TGC against CRKP and CRAB infections, as observed in our retrospective clinical cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.